News - Business (571 items)
(All links open in new tab)
| Oct 15, 2026 |
Cronos Completes Acquisition of CanAdelaar, Europe’s Largest Adult-Use Cannabis Company TORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company"), an innovative global cannabis company, today announced that it has completed its previously announced acquisition of CanAdelaar B.V. ("CanAdelaar"), the largest cannabis company operating within the Netherlands' adult-use cannabis pilot program, the Wietexperiment. |
|---|---|
| Oct 14, 2026 |
Tilray Medical Facility in Portugal Gains Approval for In-House Testing
Portugal’s National Authority of Medicines and Health Products has approved the quality control laboratory at Tilray Medical’s EU-GMP-certified facility in Cantanhede, Portugal, to conduct microbiological and chemical/physical testing in-house. The company says the INFARMED approval gives Tilray Medical greater control over critical quality testing, accelerates product release capabilities, and strengthens its Portugal facility as a strategic launchpad for medical cannabis supply across regulated international markets. |
| Oct 14, 2026 |
New cannabis packaging business launches in Canada
CropPak has launched a new cannabis packaging company and website created specifically for cannabis growers and brands. The launch marks the start of operations for the Abbotsford-based business, which was established around a factory-direct packaging model intended to help cultivators manage packaging expenses as tighter operating margins increase the importance of cost control. |
| Oct 14, 2026 |
Herbal Dispatch Ships 3,000 Units of 2026 Happy Hour Holiday Cannabis Calendar to BCLDB Following Sold-Out 2025 Edition Herbal Dispatch (LUFFF) sold and shipped 3,000 units of its 2026 Happy Hour Holiday Cannabis Calendar to the British Columbia Liquor Distribution Branch. The shipment represents over $100,000 in wholesale sales at $34.99 per unit, with an approximate gross margin of 42%. Produced with Coast Mountain Cannabis, the Calendar will reach BC Cannabis Stores and private licensed retailers. Production increased to 4,200 units, about 25% above the sold-out 2025 run of 3,350 units. |
| Oct 14, 2026 |
Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside EDMONTON, AB, Oct. 14, 2026 /CNW/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NASDAQ: ACB), the Canadian-based leading global medical cannabis company, today reconfirms that the Board of Directors (the "Board"), on the unanimous recommendation of a special committee of independent directors (the "Special Committee"), unanimously recommends that shareholders REJECT the hostile offer by Curaleaf Holdings, Inc. ("Curaleaf") (TSX: CURA) (OTCQX: CURLF) for all of the issued and outstanding common shares of the Company, as revised in the Notice of Variation, Change and Extension filed by Curaleaf on October 6, 2026 (the "Hostile Bid"). "Curaleaf's revised offer still does not reflect the value of the company Aurora shareholders own today. Aurora is debt-free with a strong cash position, and we believe the revised Hostile Bid continues to ask shareholders to give up that strength, and their future upside, at a discount," said Miguel Martin, Executive Chairman and CEO of Aurora. |
| Oct 14, 2026 |
The Aurora Ménage à Trois: Three Shifts in Seven Days
Curaleaf Holdings’ battle to acquire Aurora Cannabis has shifted in favour of the Canadian producer on multiple fronts over the last week. Not only has Curaleaf raised its hostile bid by 25% to an implied US$5.00 per share, but media reports suggest the BAT-backed (British American Tobacco) Organigram Global is now also in contention to merge with Aurora. Alongside the completion of a major expansion of its German EU-GMP facility expected to double its annual flower production, Aurora is now in a considerably stronger position than just a week earlier. |
| Oct 14, 2026 |
Cannabis prices down $1 to date in 2026 Cannabis prices hit a new low in September, falling to an average $6.57 per gram. Total sales in both the adult-use and medical markets also fell between August and September. The average price per gram of marijuana has fallen by just over a dollar in 2026. In January, marijuana averaged $7.63 a gram. Prices have generally fallen each month, except between April and May where the price per gram increased by nine cents. Marijuana prices peaked in March 2024, at an average $12.51 per gram and have largely fallen month-over-month since. The average price per adult-use product has also followed the same trend. In September, the average adult-use product cost $27.24, down from $28.09 the previous month. |
| Oct 14, 2026 |
Why Aurora Cannabis (TSX:ACB) Is Defending Its Medical Cannabis Strategy Against Curaleaf's Revised Bid Aurora Cannabis Inc. (TSX:ACB) is in the spotlight because it is defending against a hostile take-over bid from Curaleaf Holdings, Inc., which was revised in early October to an offer that Curaleaf values at US$5.00 per Aurora share. Aurora's board had said it would give a formal recommendation on the revised terms after its special committee reviews them. In the meantime it has told shareholders to take no action. The company's case for independence rests on a debt-free balance sheet, a growing international medical cannabis business and EU-GMP certified production capacity. |
| Oct 13, 2026 |
Canadian cannabis company Organigram enters fight for Aurora
The fight to acquire Aurora Cannabis may include a global tobacco giant. In a signal that Curaleaf Holdings’ hostile takeover bid could be undercut, Organigram Holdings, a Canadian licensed producer partly owned by British American Tobacco, is also interested in acquiring Aurora, cannabis newsletter Cultivated reported. |
| Oct 13, 2026 |
Cannabis Stocks in 2026: What Is Listed, What Is Next and How the Market Trades
On April 22, 2026, US Acting Attorney General Todd Blanche signed an order moving cannabis under a state medical licence and any FDA-approved cannabis drugs to Schedule III, formally recognising its medical value and unlocking DEA registration for commercial operators for the first time. While medical cannabis remained in Schedule I of the Controlled Substances Act (CSA), a company whose primary business is growing and selling cannabis could not accurately state that it complied with federal law and thus couldn’t meet the listing requirements for both NYSE and NASDAQ. As such, until this change, cannabis operators have been effectively locked out of major US exchanges due to the federal illegality of cannabis. For the first time in the industry’s history, US cannabis operators had a path to list their stocks on blue-chip exchanges. |
| Oct 12, 2026 |
Overseed: France's First Medical Cannabis Biotech Company
Overseed is one of the startups aiming to make France a producer of medical cannabis—rather than just a market supplied by imports from Canada or the Netherlands. Founded in Orléans in 2021 by Hugues Péribère, one of the first biotech companies approved by the ANSM for R&D in pharmaceutical cannabis production, the company is patiently building the value chain that would one day enable France to have its own domestically produced 100% cannabis-based medications. |
| Oct 12, 2026 |
California Cannabis Dispensary Launch First RFID-Powered Technology Perfect Union Northside dispensary in Sacramento has become the first licensed cannabis retailer in California approved by the California Department of Cannabis Control (DCC) to launch RFID-powered self-checkout technology through EXO, marking a significant milestone in the evolution of cannabis retail. Following a successful observation and review by state regulators, Perfect Union Northside received confirmation that the EXO self-checkout system could remain on the sales floor and continue operating while maintaining compliance with California cannabis regulations. |
| Oct 10, 2026 |
Curaleaf 'Outraged' by Reported Competing Offer for Aurora Cannabis
Curaleaf may be facing some competition as it pursues a hostile takeover bid for Aurora Cannabis. According to Cultivated, Organigram Global, a Canada-based cannabis operator, has been in talks with Aurora for the past few weeks regarding a potential merger. Neither company would confirm the discussions, but Curaleaf has already blasted the idea of the two companies pursuing any type of M&A. |
| Oct 10, 2026 |
Top Cannabis Stocks To Add to Your Watchlist - October 10th
Tilray Brands, Trulieve Cannabis, Glass House Brands, Aurora Cannabis, Canopy Growth, Cronos Group, and High Tide are the seven Cannabis stocks to watch today, according to MarketBeat's stock screener tool. Cannabis stocks are shares of publicly traded companies involved in the cultivation, production, distribution, retail, or ancillary services related to cannabis and cannabis-derived products. For stock market investors, they represent an opportunity to gain exposure to the cannabis industry but may carry heightened risks due to regulatory uncertainty, changing laws, market volatility, and evolving consumer demand. These companies had the highest dollar trading volume of any Cannabis stocks within the last several days. |
| Oct 9, 2026 |
Aurora Completes Major Expansion of European EU-GMP Manufacturing Facility, More Than Doubling Expected Annual Flower Output
EDMONTON, AB, Oct. 8, 2026 /CNW/ -- Aurora Cannabis Inc. (TSX: ACB) (NASDAQ: ACB), the leading Canadian-based global medical cannabis company, today announced the completion of a major expansion of its facility in Leuna, Germany. The expansion project establishes the Leuna facility as a manufacturing site of excellence, incorporating proven cultivation and post-harvest practices from Aurora's Canadian operations alongside the company's proprietary genetics and product catalogue. The expanded facility has increased cultivation capacity while improving product quality, consistency and operational efficiency, strengthening the facility's role in serving Aurora's growth in Europe. |
| Oct 9, 2026 |
Legacy medical cannabis cultivator Bedrocan declared bankrupt in Netherlands
The Netherlands will shift to international cannabis imports for its domestic MMJ supply after a Dutch court declared Bedrocan, the country’s sole licensed cultivator and one of the oldest medical cannabis companies in the world, bankrupt on Thursday. Bedrocan’s ongoing woes follow the termination on Jan. 1 of its contract with the state health ministry, the company’s biggest client, to supply domestic medical cannabis patients, as Dutch News reported. |
| Oct 9, 2026 |
Federal marijuana rescheduling means institutional capital is coming to cannabis investing The U.S. cannabis industry has spent years waiting for a single catalyst from the federal government to change its trajectory. Investors have watched for banking reform, rescheduling, federal legalization and tax relief as though one event might suddenly erase the barriers that have kept traditional capital on the sidelines. After more than three decades in capital markets, I do not think industries mature that way. Capital tends to move when a series of risks become measurable, familiar and ultimately manageable. |
| Oct 8, 2026 |
Tilray Brands Sinks 4% as Record Revenue Masks Shrinking Cannabis Sales; Canopy Growth and Aurora Cannabis Ease Quick Read TLRY fell 7% after cannabis revenue shrank while beer drove a 23% revenue record; CGC and ACB each dipped just 1%. MJ and SPY each fell just 0.3%, confirming the selloff targets Tilray Brands specifically rather than the broader cannabis sector. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Tilray Brands didn't make the cut. Enter your email to see the names that beat TLRY. The report is free. Enter your email and see if any of your stocks made the cut. |
| Oct 8, 2026 |
Europe Now a Growth Priority for North American Cannabis Capital
North American institutional cannabis investors now see the European medical market as a crucial driver of growth, a new survey suggests. ATB Cormark Capital Markets’ latest ‘Capital Markets Cannabis Investor Sentiment Survey’ found that nearly half (47.1%) of US-focused respondents believe multi-state operators (MSOs) should participate in international medical cannabis markets, up from 37.5% in Spring 2026, with the share saying MSOs should not participate collapsing from 37.5% to 11.8%. |
| Oct 8, 2026 |
Tilray posts record revenue but cannabis sales drop, shares fall 4% amid profit pressure
Tilray Brands reported a first-quarter revenue record, rising 23% year-over-year, driven by gains in its beer and distribution segments following the BrewDog acquisition. However, its core cannabis sales declined, falling to $56.1 million, causing investor concern and a 4% drop in its stock price. Despite higher revenue and gross profit, adjusted earnings before interest, taxes, depreciation, and amortization decreased due to factors like global fuel surcharges. The company remains optimistic with a net cash position and reduced debt, but the market will watch closely to see if cannabis sales stabilize and profitability improves in coming quarters. Canopy Growth and Aurora Cannabis, more focused on cannabis, showed smaller stock declines, indicating Tilray's mixed results are company-specific rather than sector-wide. |